A Phase 3 interventional study of Coenzyme Q10 100 Milligrams Oral Capsule and Selenium 100 Micrograms Oral Tablets in Heart Failure, sponsored by Tor Biering-Sørensen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Tor Biering-Sørensen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 242 studies in Heart Failure with a site in Denmark — 52 open to participants now, 60 under way, 9 of them phase 3. Heart Failure · Denmark.
Among the 242 studies in Heart Failure with a site in Denmark, this one is the 24th largest by planned enrollment of the 187 interventional ones that give a count, is one of 10 that started in 2025, is one of 38 in phase 3, reaches primary completion later than 38 of the 59 other live ones, and was the 221st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →52 of the 242 studies in Heart Failure with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark, Finland, Norway and 1 more country
Ages 18–99
University of Aarhus · Sites in Denmark
Ages 18+
Novo Nordisk A/S · Sites in Denmark, United States, Argentina and 24 more countries
Ages 18+
Gødstrup Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
242 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 39 · Phase 3 43 · Phase 4 15
First in 1983; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,044 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 197 across the 187 interventional studies, 213 across the 54 observational. Of the 159 that completed or were terminated, 55 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 242 have an industry lead sponsor. The 10 most frequent:
Tor Biering-Sørensen is the lead sponsor of 22 studies on the registry; 11 are open to participants now.
Tor Biering-Sørensen has 3 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04709900Copenhagen University Hospital, RigshospitaletCT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes | 2026-12 |
| NCT05104658Center for Clinical Research and PreventionHeart Rehabilitation for All | 2026-12-31 |
| NCT05063955Aarhus University HospitalMechanism of Sarcopenia in Heart Failure | 2026-12-31 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT05834803University of AarhusEffects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients. | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 242 studies in Heart Failure with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart failure is a common and serious condition. Despite rapid advancements in heart failure treatment, the prognosis remains severe. Smaller studies have shown that two simple, safe, and relatively inexpensive nutritional supplements-coenzyme Q10 and selenium-may reduce the risk of complications associated with heart failure. The DANUTRIO-HF trial will investigate whether these supplements can make a difference for individuals with heart failure. The study will assign approximately 4,044 patients from across Denmark to either coenzyme Q10 (100 mg twice daily) or a corresponding placebo, as well as selenium (100 μg twice daily) or its corresponding placebo, and follow how many of them end up being hospitalized for heart failure or dying from heart problems over an estimated two to three-year period.
This investigator-initiated, pragmatic, registry-based, double-blinded, placebo-controlled, 2x2 factorial, individually randomized trial aims to evaluate the efficacy of daily intake of the nutritional supplements coenzyme Q10 versus placebo, and selenium versus placebo, in preventing heart failure hospitalizations and cardiovascular death in heart failure patients. The trial plans to randomize approximately 4,044 participants in an event-driven design. Participants will be identified through the Danish Administrative Health Registries, which will also serve as the primary source for data collection. Contact with potential participants will be made via the mandatory Danish electronic letter system. No scheduled in-person visits are required in the main study, and all study interventions will be mailed to participants.
A substudy involving up to 600 participants will assess the effects of coenzyme Q10 and selenium on functional capacity, treatment compliance, biochemical biomarkers, and cardiac function and structure. This group will attend two in-person visits for additional evaluations, including echocardiography, blood sampling, and a 6-minute walk test at baseline and at the 1-year follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg capsules given twice daily, per oral use
Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule
Placebo matching coenzyme Q10
Dietary Supplement: Coenzyme Q10 100 Milligrams Oral Capsule
100 μg tables given twice daily, per oral use
Dietary Supplement: Selenium 100 Micrograms Oral Tablets
100 μg tables given twice daily, per oral use
Dietary Supplement: Selenium 100 Micrograms Oral Tablets
100 mg capsules given twice daily, per oral use.
100 μg tablets given twice daily, per oral use.
Time to the first occurrence of hospitalization for heart failure or cardiovascular death
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first occurrence of hospitalization for heart failure
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to cardiovascular death
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for heart failure
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for heart failure and cardiovascular death
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to the first occurrence of hospitalization for heart failure or all-cause death
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for heart failure and all-cause death
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to all-cause mortality
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first occurrence of major adverse cardiovascular events
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of major adverse cardiovascular events
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first occurrence of hospitalization for any cardiovascular disease
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for any cardiovascular disease
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first occurrence of hospitalization for any cardiorespiratory disease
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for any cardiorespiratory disease
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first hospitalization for atrial fibrillation
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for atrial fibrillation
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first occurrence of hospitalization for cardiac arrest
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Time to first hospitalization for any cause
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Total number of hospitalizations for any cause
Time frame: From date of randomization until end of study (Up to approximately 33 months)
Change in Kansas City Cardiomyopathy Questionnaire Score
Time frame: Aproximately within 1 year after randomization
Change in left ventricular ejection fraction assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left ventricular global longitudinal strain assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in E/e'-ratio assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left ventricular mass assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in interventricular septal wall thickness assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left ventricular posterior thickness assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left atrial volume assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left atrial resevoir strain assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left atrial contraction strain assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in left atrial conduit strain assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in tricuspid annular plane systolic excursion assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in right ventricular free wall longitudinal strain assessed with echocardiography
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in pro-BNP
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in high sensitivity troponin-I
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in hs-CRP
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Concentration of coenzyme Q10 at followup
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Concentration of selenoprotein P and selenium at followup
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Change in 6 minute walking distance
In up to 600 participants in a planned substudy with two physical visits. One shortly after randomization and another 1 year after
Time frame: Aproximately within 1 year after randomization
Plan to share: Yes — Most data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 38 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tor Biering-Sørensen